Pomalidomide/daratumumab/dexamethasone in relapsed or refractory multiple myeloma: Final overall survival from MM-014

The 3-cohort phase 2 MM-014 trial looked into using pomalidomide in early lines of treatment for lenalidomide-exposed relapsed or refractory multiple myeloma. At a median follow-up of 41.9 months (range, 0.4-73.1), median overall survival was 56.7 months (95% confidence interval, 46.5-not reached). As previously reported, in cohort B, pomalidomide plus daratumumab and dexamethasone showed promising efficacy (median follow-up 28.4 months).